Skip to main content
SpringerLink
Log in

Juvenile Rheumatoid Arthritis

Therapeutic Perspectives

  • Review Article
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

Juvenile rheumatoid arthritis (JRA) is the most common childhood chronic systemic autoimmune inflammatory disease. The therapeutic approach to JRA has, to date, been casual and based on extensions of clinical experiences gained in the management of adult rheumatoid arthritis (RA). The physiology of inflammation has been systemically studied and this has led to the identification of specific therapeutic targets and the development of novel approaches to the management of JRA.

The classical treatments of the disease such as methotrexate, sodium aurothiomalate and sulfasalazine, are not always effective in controlling RA and JRA. This has necessitated the development of novel agents for treating RA, most of which are biological in nature and are targeted at specific sites of the inflammatory cascades. These biological therapeutic strategies in RA have proved successful and are being applied in the management of JRA. These developments have been facilitated by the advances in molecular biology which have heralded the advent of biodrugs (recombinant proteins) and gene therapy, in which specific genes can be introduced locally to enhance in vivo gene expression or suppress gene(s) of interest with a view to down-regulating inflammation.

Some of these biodrugs, such as anti-tumor necrosis factor α (anti-TNFα), monoclonal antibodies (infliximab, adalimumab), TNF soluble receptor constructs (etanercept) and interleukin-1 receptor antagonist (IL-1Ra) have been tested and shown to be effective in RA. Etanercept has now been licensed for JRA. Clinical trials of infliximab in JRA are planned. Studies show that the clinical effects are transient, necessitating repeated treatments and the risk of vaccination effects. Anti-inflammatory cytokines such as IL-4, IL-10, transforming growth factor-β and interferon-β (IFN-β) are undergoing clinical trials. Many of these agents have to be administered parenterally and production costs are very high; thus, there is a need, especially for pediatric use, to develop agents that can be taken orally. Long-term studies will be required to assess the tolerability and toxicity of these approaches in JRA, since cytokines and other mediators play important roles in host defenses, and the chronic inhibition, exogenous administration or constitutive over-expression of some cytokines/mediators may have undesirable effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

References

  1. Ansell BM, Bywaters EGL. Growth in Still’s disease. Ann Rheum Dis 1956; 15: 295–9

    PubMed  CAS  Google Scholar 

  2. Bernstein BH, Stobie D, Singsen BH, et al. Growth retardation in juvenile rheumatoid arthritis. Arthritis Rheum 1977; 20(2 Suppl.): 212–6

    PubMed  CAS  Google Scholar 

  3. Towner SR, Michet Jr CJ, O’Fallon WM, et al. The epidemiology of juvenile rheumatoid arthritis in Rochester, Minnesota. Arthritis Rheum 1983; 26: 1208–13

    PubMed  CAS  Google Scholar 

  4. Petty RE, Southwood TR, Baum J, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 1998; 25: 1991–4

    PubMed  CAS  Google Scholar 

  5. Chikanza IC, Fernandes L. The current and future prospects for biological targeted therapies for rheumatoid arthritis. Exp Opin Invest Drugs 1996; 5(7): 819–28

    CAS  Google Scholar 

  6. Maini RN, Feldman M. Immunopathogenesis of rheumatoid arthritis. In: Maddison PS, editor. Oxford textbook of rheumatology. Oxford: Oxford Medical Publications, 1993: 621–38

    Google Scholar 

  7. Chikanza IC, Grossman AS. Neuroendocrine immune responses to inflammation: the concept of the neuroendocrine immune loop. Bailliere’s Clin Rheumatol 1996; 10: 199–225

    CAS  Google Scholar 

  8. Chikanza IC. Neuroendocrine immune features of paediatric inflammatory rheumatic diseases. Ann N Y Acad Sci 1999; 876: 71–82

    PubMed  CAS  Google Scholar 

  9. Linsley PS, Greene JL, Tan P, et al. Co-expression and functional co-operation of CTLA4 and CD28 on activated lymphocytes. J Exp Med 1992; 176: 1595–604

    PubMed  CAS  Google Scholar 

  10. Akira S, Hirano T, Taga T, et al. Biology of multi-functional cytokines: IL-6 and related molecules (IL-1 and TNF). FASEB J 1990; 4: 2860–7

    PubMed  CAS  Google Scholar 

  11. Hanamaijer R, Koolwijk P, Le Clercq L. Regulation of metalloproteinase expression in human vein and microvascular endothelial cells. Biochem J 1993; 296: 803–9

    Google Scholar 

  12. Mackay CR, Imhof BA. Cell adhesion in the immune system. Immunol Today 1993; 14: 99–102

    PubMed  CAS  Google Scholar 

  13. Chikanza IC. Prolactin and neuroimmunomodulation: in vitro and in vivo observations. Ann N Y Acad Sci 1999; 876: 131–44

    Google Scholar 

  14. Chikanza IC, Petrou P, Chrousos G. Pertubations of arginine vasopressin secretion during inflammatory stress: pathophysiologic implications. Ann N Y Acad Sci 2000; 917: 823–34

    Google Scholar 

  15. Woo P. The cytokine network in juvenile chronic arthritis. Ann Med 1997; 29: 145–7

    PubMed  CAS  Google Scholar 

  16. Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 2000; 39(6): 655–65

    PubMed  CAS  Google Scholar 

  17. Malleson PN, Petty RE. Remodelling the pyramid: a paediatric perspective. J Rheumatol 1990; 17: 867–8

    PubMed  CAS  Google Scholar 

  18. Schaller JG. Therapy for childhood rheumatic diseases: have we been doing enough? Arthritis Rheum 1993; 36: 65–70

    PubMed  CAS  Google Scholar 

  19. Lehman TJ. Aggressive therapy for childhood rheumatic diseases: when are immunosuppressives appropriate? Arthritis Rheum 1993; 36: 71–4

    PubMed  CAS  Google Scholar 

  20. Baron KS, Person DA, Brewer EJ. The toxicity of nonsteroidal anti-inflammatory drugs in juvenile rheumatoid arthritis. J Rheumatol 1982; 9: 149–55

    Google Scholar 

  21. Hermaszewski R, Hayllar J, Woo P. Gastro-intestinal damage due to anti-inflammatory drugs in children. Br J Rheumatol 1993; 32: 69–72

    PubMed  CAS  Google Scholar 

  22. Levy ML, Barron KS, Echenfield J, et al. Naproxen-induced pseudoporphyria: a distinctive photodermatosis. J Pediatr 1990; 117: 660–4

    PubMed  CAS  Google Scholar 

  23. Kauffman RE, Roberts RJ. Aspirin use and Reye syndrome. Pediatrics 1987; 79: 1049–50

    PubMed  CAS  Google Scholar 

  24. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 inhibitors selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104: 413–21

    PubMed  CAS  Google Scholar 

  25. Chikanza IC, Jawed S, Naughton D, et al. Why do we need new treatments for rheumatoid arthritis? J Pharm Pharmacol 1998; 50: 357–69

    PubMed  CAS  Google Scholar 

  26. Pincus P. The paradox of effective therapies but poor long-term outcomes in rheumatoid arthritis. Sem Arthritis Rheum 1992; 21: 2–15

    CAS  Google Scholar 

  27. Boers M, Tugwell P, Felston DT, et al. WHO and ILAR core end points for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol 1994; 21: 86–9

    Google Scholar 

  28. Giannini EH, Cassidy JT. Methotrexate in juvenile rheumatoid arthritis: do the benefits outweigh the risks? Drug Saf 1993; 9: 325–39

    PubMed  CAS  Google Scholar 

  29. Jolivet J, Cowan KH, Chabner BA, et al. The pharmacology and clinical use of methotrexate. N Engl J Med 1983; 309: 1094–102

    PubMed  CAS  Google Scholar 

  30. Cronstein BN, Eberle MA, Gruber HE, et al. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci USA 1991; 88: 2441–5

    PubMed  CAS  Google Scholar 

  31. Cronstein BN, Naime D, Ostad E. The anti-inflammatory mechanisms of methotrexate: increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993; 92: 2675–82

    PubMed  CAS  Google Scholar 

  32. Cronstein BN, Kramer SB, Weissmann G, et al. Adenosine a physiological modulator of Superoxide anion generation by human neutrophils. J Exp Med 1983; 158: 1160–77

    PubMed  CAS  Google Scholar 

  33. Bouma MG, van den Wildenburg FAJM, Buurman MA. Adenosine inhibits cytokine release and expression of adhesion molecules by activated human monocytes. J Immunol 1994; 153: 4159–68

    PubMed  CAS  Google Scholar 

  34. Cronstein BN, Levin RI, Philips MR, et al. Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via A2 receptors. J Immunol 1992; 148: 2201–6

    PubMed  CAS  Google Scholar 

  35. Krump E, Lemay G, Borgeat P. Adenosine A2 receptor mediated inhibition of leukotriene B4 synthesis in whole blood ex vivo. Br J Pharmacol 1996; 117: 1639–44

    PubMed  CAS  Google Scholar 

  36. Thiel M, Chouker A. Acting via A2 receptors, adenosine inhibits production of TNF of endotoxin stimulated polymorphonuclear leukocytes. J Lab Clin Med 1995; 126: 275–82

    PubMed  CAS  Google Scholar 

  37. Bouma MG, Stad RK, van den Wildenberg FAJM, et al. Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J Immunol 1994; 153: 4159–68

    PubMed  CAS  Google Scholar 

  38. Cronstein BN, Naime D, Firestein GS. The anti-inflammatory effects of an adenosine kinase inhibitor are mediated by adenosine. Arthritis Rheum 1995; 38: 1040–5

    PubMed  CAS  Google Scholar 

  39. Le Moine O, Stordeur P, Schandene L, et al. Adenosine enhances IL-10 secretion by human monocytes. J Immunol 1996; 156: 4408–14

    PubMed  Google Scholar 

  40. Schrier DJ, Lesch ME, Wright CD, et al. The anti-inflammatory effects of adenosine receptor agonists on the carrageenan-induced pleural inflammatory response in rats. J Immunol 1990; 145: 1874–9

    PubMed  CAS  Google Scholar 

  41. Merrill JT, Coffey D, Shen C, et al. Mechanisms of rheumatoid nodulosis: methotrexate-enhanced monocyte fusion requires protein synthesis and intact microtubules. Arthritis Rheum 1995; 38 Suppl.: 157–62

    Google Scholar 

  42. Giannini EH, Brewer EJ, Kusmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis: results of the USA-USSR double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children’s Study Group. N Engl J Med 1992; 326: 1043–9

    PubMed  CAS  Google Scholar 

  43. Wallace CA, Sherry DD. Preliminary report of higher dose methotrexate treatment in juvenile rheumatoid arthritis. J Rheumatol 1992; 19: 1604–7

    PubMed  CAS  Google Scholar 

  44. Reiff A, Shaham B, Wood BP, et al. High dose methotrexate in the treatment of refractory juvenile rheumatoid arthritis. Clin Exp Rheumatol 1995; 13: 113–8

    PubMed  CAS  Google Scholar 

  45. Ravelli A, Gerloni V, Corona F, et al. Oral versus intramuscular methotrexate therapy in juvenile chronic arthritis. Italian Pediatric Rheumatology Study Group. Clin Exp Rheumatol 1998; 16: 181–3

    PubMed  CAS  Google Scholar 

  46. Specimaier M, Finseiden J, Wood P, et al. Low dose methotrexate in systemic onset juvenile chronic arthritis. Clin Exp Rheumatol 1989; 7: 647–50

    Google Scholar 

  47. Halle F, Prieur AM. Evaluation of methotrexate in the treatment of juvenile chronic arthritis according to the subtype. Clin Exp Rheumatol 1991; 9: 297–302

    PubMed  CAS  Google Scholar 

  48. Woo P, Wilkes H, Southwood TR, et al. Low dose methotrexate is effective in extended oligoarticular arthritis but not in systemic arthritis of children. Arthritis Rheum 1997; 40: S47

    Google Scholar 

  49. Harel L, Wagner-Weiner L, Poznanski A, et al. Effects of methotrexate on radiologic progression in juvenile rheumatoid arthritis. Arthritis Rheum 1993; 36: 1370–4

    PubMed  CAS  Google Scholar 

  50. Ravelli A, Viola S, Ramenghi B, et al. Radiologic progression in patients with juvenile chronic arthritis treated with methotrexate. J Pediatr 1998; 133: 179–80

    Google Scholar 

  51. Weiss AH, Wallace CA, Sherry DD. Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis. J Pediatr 1998; 133: 266–8

    PubMed  CAS  Google Scholar 

  52. Wallace C, Sherry D, Mellins E, et al. Predicting remission in juvenile rheumatoid arthritis with methotrexate treatment. J Rheumatol 1993; 20: 118–22

    PubMed  CAS  Google Scholar 

  53. Ravelli A, Viola S, Ramenghi B, et al. Frequency of relapse after discontinuation of methotrexate therapy in clinical remission juvenile rheumatoid arthritis. J Rheumatol 1995; 22: 1574–6

    PubMed  CAS  Google Scholar 

  54. Graham L, Myones B, Rivas-Chacon R, et al. Morbidity associated with long-term methotrexate therapy in juvenile rheumatoid arthritis. J Pediatr 1992; 120: 468–73

    PubMed  CAS  Google Scholar 

  55. Cron R, Sherry DD, Wallace CA. Methotrexate-induced hypersensitivity pneumonitis in a child with juvenile rheumatoid arthritis. J Pediatr 1998; 132: 901–2

    PubMed  CAS  Google Scholar 

  56. Seideman P, Müller-Suur R. Renal effect off aspirin and low dose methotrexate in rheumatoid arthritis. J Rheumatol 1993; 20: 1126–8

    PubMed  CAS  Google Scholar 

  57. Muzaffer MA, Schneider R, Cameron BJ, et al. Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis. J Pediatr 1996; 128: 698–700

    PubMed  CAS  Google Scholar 

  58. Falcini F, Taccetti G, Ermini M, et al. Methotrexate-associated appearance and rapid progression of rheumatoid nodules in systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 1997; 40: 175–8

    PubMed  CAS  Google Scholar 

  59. Wheeler DL, vander Griend RA, Wrongski TJ, et al. The short and long-term effects of methotrexate on the rat skeleton. Bone 1995; 16: 215–21

    PubMed  CAS  Google Scholar 

  60. Modesto C, Castro L. Folinic acid supplementation in patients with juvenile rheumatoid arthritis treated with methotrexate. J Rheumatol 1996; 23: 403–4

    PubMed  CAS  Google Scholar 

  61. Morgan SL, Baggott JE, Alarcon GS, et al. Leucovorin versus folic acid in the treatment of methotrexate toxicity [comment]. Arthritis Rheum 1994; 37: 444–5

    PubMed  CAS  Google Scholar 

  62. Davis P. Undesirable side effects of gold salts. J Rheumatol 1979; 6: 18–24

    Google Scholar 

  63. Brewer EJ, Giannini EH, Barkley E. Gold therapy with management of juvenile rheumatoid arthritis. Arthritis Rheum 1980; 23: 404–11

    PubMed  Google Scholar 

  64. Debenetti C, Tretbar H, Corrigan JJ. Gold therapy in juvenile rheumatoid arthritis. Ariz Med 1976; 33: 373–6

    Google Scholar 

  65. Sairanen E, Laaksonen AL. The results of gold therapy in juvenile rheumatoid arthritis. Ann Paediatr Fenn 1963; 8: 105

    Google Scholar 

  66. Grondin C, Malleson P, Petty RE. Slow-acting anti-rheumatic drugs in chronic arthritis. Semin Arthritis Rheum 1988; 18: 38–47

    PubMed  CAS  Google Scholar 

  67. Giannini EH, Cassidy JT, Brewer EJ, et al. Comparative efficacy and safety of advanced drug therapy in children with juvenile rheumatoid arthritis. Semin Arthritis Rheum 1993; 23: 34–6

    PubMed  CAS  Google Scholar 

  68. Hadchouel M, Prieur AM, Griscelli C. Acute hemorrhagic, hepatic and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J. Pediatr 1985; 106: 561–6

    CAS  Google Scholar 

  69. Brewer EJ, Giannini EH, Pearson DA. Early experiences with auranofin in juvenile RA. Am J Med 1983; 75: 152–6

    PubMed  Google Scholar 

  70. Giannini EH, Brewer EJ, Person DA. Auranofin in the treatment of juvenile rheumatoid arthritis. J Pediatr 1983; 103: 138–41

    Google Scholar 

  71. Giannini EH, Brewer EJ, Person DA, et al. Long-term auranofin in the treatment of juvenile rheumatoid arthritis. J Rheumatol 1986; 13: 768–70

    PubMed  CAS  Google Scholar 

  72. Brewer EJ, Giannini EH. Oral gold (auranofin) in juvenile rheumatoid arthritis: results of the double-blind placebo controlled trial. Arthritis Rheum 1987; 30 Suppl.: S31

    Google Scholar 

  73. Giannini EH, Brewer Jr EH, Kuzmina N, et al. Auranofin in the treatment of juvenile rheumatoid arthritis: results of the USA-USSR double-blind placebo-controlled trial. Arthritis Rheum 1990; 33: 466–72

    PubMed  CAS  Google Scholar 

  74. Svartz N. Salazopyrin, a new sulfanilamide preparation. Acta Med Scand 1942; 60: 577–81

    Google Scholar 

  75. Svart N. The treatment of rheumatoid arthritis with acid azo compounds. Rheumatism 1948; 4: 56–61

    Google Scholar 

  76. Imundo LF, Jacobs JC. Sulfasalazine therapy for juvenile rheumatoid arthritis. J Rheumatol 1996; 23: 360–6

    PubMed  CAS  Google Scholar 

  77. Thayer Jr WR, Charland C, Field CE. Effects of sulfasalazine on selected lymphocyte subpopulations in vitro and in vivo. Dig Dis Sci 1979; 24: 672–9

    PubMed  CAS  Google Scholar 

  78. Heickly FE, Buckley RH. Development of IgA and IgG2 subclass deficiency after sulfasalazine. J Pediatr 1986; 108: 481–2

    Google Scholar 

  79. Stenson WF, Lobos E. Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils. J Clin Invest 1982; 69: 494–7

    PubMed  CAS  Google Scholar 

  80. Capell HA, Pullar T, Hunter JA. Comparison of white blood cell dyscrasias during sulfasalazine therapy of rheumatoid arthritis and inflammatory bowel disease. Drugs 1986; 32Suppl. 1: 44–8

    PubMed  Google Scholar 

  81. Schroeder H, Campbell DES. Absorption, metabolism and excretion of salicylazosulfapyridine in man. Clin Pharmacol Ther 1972; 13: 539–51

    Google Scholar 

  82. Ansell BM, Hall JK, Lofus P, et al. A multicentre pilot study of sulphasalazine in juvenile chronic arthritis. Clin Exp Rheumatol 1991; 9: 201–3

    PubMed  CAS  Google Scholar 

  83. Ozdogan H, Turunc M, Deringol B, et al. Sulphasalazine in the treatment of juvenile rheumatoid arthritis: a preliminary open trial. J Rheumatol 1986; 13: 124–5

    PubMed  CAS  Google Scholar 

  84. Van Rossum MA, Fiselier TJ, Franssen MJ, et al. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study. Arthritis Rheum 1998; 41: 808–16

    PubMed  Google Scholar 

  85. Laaksonen AL, Koskiahde V, Juva K. Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus: a clinical study with determination of serum concentrations of chloroquine and hydroxychloroquine. Scand J Rheumatol 1974; 3: 103–8

    PubMed  CAS  Google Scholar 

  86. Stillman JS. Antimalarials in the treatment of juvenile rheumatoid arthritis. In: Moore TD, editor. Arthritis in childhood. Columbus (OH): Ross Laboratories, 1981: 125–30

    Google Scholar 

  87. Logan ECM, Williamson LM, Ryrie DR. Sulfasalazine associated pancytopenia may be caused by acute folate deficiency. Gut 1986; 27: 868–72

    PubMed  CAS  Google Scholar 

  88. Prouse PJ, Shawe D, Gumpel JM. Macrocytic anaemia in patients treated with sulfasalazine for rheumatoid arthritis. BMJ 1986; 293: 1407

    PubMed  CAS  Google Scholar 

  89. Clementz GL, Dolin BJ. Sulfasalazine-induced lupus erythematosus. Am J Med 1988; 84 (3 Pt 1): 535–8

    PubMed  CAS  Google Scholar 

  90. Reid J, Holt S, Housley E, et al. Raynaud’s phenomenon induced by sulphasalazine. Postgrad Med J 1980; 56: 106–7

    PubMed  CAS  Google Scholar 

  91. Averbuch M, Halpern Z, Hallak A, et al. Sulfasalazine pneumonitis. Am J Gastroenterol 1985; 80: 343–5

    PubMed  CAS  Google Scholar 

  92. Hamadeh MA, Atkinson J, Smith LJ. Sulfasalazine induced pulmonary disease. Chest 1992; 101: 1033–7

    PubMed  CAS  Google Scholar 

  93. Caspi D, Fuchs D, Yaron M. Sulphasalazine induced hepatitis in juvenile rheumatoid arthritis. Ann Rheum Dis 1992; 51: 275–6

    PubMed  CAS  Google Scholar 

  94. Kummerle-Deshner J, Danneker G. Sulphasalazine desensitization in a paediatric patient with juvenile chronic arthritis. Acta Paediatr 1995; 84: 952–4

    Google Scholar 

  95. Brewer EJ, Giannini EH, Kuzmina H, et al. Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis: results of the USA-USSR double-blind placebo-controlled trial. N Engl J Med 1986; 314: 1269–76

    PubMed  CAS  Google Scholar 

  96. Schaire H, Stoeber E. Long term follow-up of 235 cases of JRA treated with d-penicillamine. In: Munther E, editor. Penicillamine research in rheumatoid disease. Oslo: Fabricius & Sonner Publisher, 1977: 279–80

    Google Scholar 

  97. Prieur AM, Piussan C, Manigne P, et al. Evaluation of D-penicillamine in juvenile chronic arthritis. Arthritis Rheum 1985; 28: 376–82

    PubMed  CAS  Google Scholar 

  98. Førre O, Munthe E, Kass E. Side-effects and auto-immunogenicity of D-Penicillamine treatment in rheumatic diseases [abstract]. Adv Inflamm Res 1984; 6: 251

    Google Scholar 

  99. Takahashi K, Ogita T, Okudaira H, et al. D-penicillamine-induced polymyositis in patients with rheumatoid arthritis. Arthritis Rheum 1986; 29: 560–4

    PubMed  CAS  Google Scholar 

  100. Kuncle RW, Restronk A, Drachman DB, et al. The pathophysiology of penicillamine-induced myasthenia gravis. Ann Neurol 1986; 20: 740–4

    Google Scholar 

  101. Enzenauer RJ, Sterling GW, Rubin RL. D-penicillamine induced lupus erythematosus. Arthritis Rheum 1990; 33: 1582–5

    PubMed  CAS  Google Scholar 

  102. Cato ACB, Wade E. Molecular mechanisms of anti-inflammatory action of glucocorticosteroids. BioAssays 1996; 18: 371–8

    CAS  Google Scholar 

  103. Auphan N, Didonato JA, Rosette C, et al. Immunosuppression by glucocorticosteroids: inhibition of NF-κ6B activity through induction of I6B synthesis. Science 1995; 270: 286–90

    PubMed  CAS  Google Scholar 

  104. Chikanza IC, Grossman AS. Reciprocal interactions between the neuroendocrine and immune systems. In: Masi AL, Chikanza IC, Bijlsma JWJ, et al., editors. Rheumatic disease clinics of North America: neuroendocrine mechanisms in rheumatic diseases. Philadelphia (PA): WB Saunders Company, 2000; 26: 693–712

    CAS  Google Scholar 

  105. Svantessor H. Treatment of growth failure with human growth hormone in patients with juvenile chronic arthritis: a pilot study. Clin Exp Rheumatol 1994; 9Suppl. 6: 47–50

    Google Scholar 

  106. Davies UM, Rooney M, Preece MA, et al. Treatment of growth retardation in juvenile chronic arthritis with recombinant human growth hormone. J Rheumatol 1994; 21: 153–8

    PubMed  CAS  Google Scholar 

  107. Touati G, Prieur AM, Ruiz JC, et al. Beneficial effects of one year growth hormone administration to children with juvenile chronic arthritis on chronic steroid therapy, I: effects on growth velocity and body composition. J Endocrinol Metab 1998; 83: 403–9

    CAS  Google Scholar 

  108. Miller III JJ. Prolonged use of large intravenous steroid pulses in the rheumatic diseases of children. Pediatrics 1980; 65: 989–94

    PubMed  Google Scholar 

  109. Adebajo AO, Hall MA. The use of intravenous pulsed methylprednisolone in the treatment of systemic-onset juvenile chronic arthritis. Br J Rheumatol 1998; 37: 1240–2

    PubMed  CAS  Google Scholar 

  110. Allen RC, Gross KR, Laxer RM, et al. Intra-articular triamcinolone hexacetonide in the management of chronic arthritis in children. Arthritis Rheum 1986; 29: 997–1001

    PubMed  CAS  Google Scholar 

  111. Earley A, Cuttica RJ, McCullough C, et al. Triamcinolone into the knee joint in juvenile chronic arthritis. Clin Exp Rheumatol 1988; 6: 153–5

    PubMed  CAS  Google Scholar 

  112. Sparling M, Malleson P, Wood B, et al. Radio-graphic follow-up of joints injected with triamcinolone hexacetonide for the management of childhood arthritis. Arthritis Rheum 1990; 33: 821–6

    PubMed  CAS  Google Scholar 

  113. Job-Deslandre C, Menkes CJ. Complications of intra-articular injections of triamcinolone hexacetonide in chronic arthritis in children. Clin Exp Rheumatol 1990; 8: 413–6

    PubMed  CAS  Google Scholar 

  114. Earley A, Cuttica R, McCullough C, et al. Triamcinolone hexacetonide into the knee joint in juvenile chronic arthritis. Clin Exp Rheumatol 1988; 6: 153–5

    PubMed  CAS  Google Scholar 

  115. Cassidy JT, Bole GG. Cutaneous atrophy secondary to intra-articular corticosteroid administration. Ann Intern Med 1966; 65: 1008–18

    PubMed  CAS  Google Scholar 

  116. Gilsanz V, Bernstein BH. Joint calcification following intra-articular corticosteroid therapy. Radiology 1984; 151: 647–9

    PubMed  CAS  Google Scholar 

  117. Silverman ED, Laxer RM, Greenwald M, et al. Intravenous immunoglobulin therapy in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1990; 33: 1015–22

    PubMed  CAS  Google Scholar 

  118. Prieur AM, Adleff A, Debre M, et al. High dose immunoglobulin in the treatment of systemic juvenile chronic arthritis. Clin Exp Rheumatol 1990; 8: 603–9

    PubMed  CAS  Google Scholar 

  119. Arend WP, Dayer JM. Cytokines and cytokines inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990; 33: 305–15

    PubMed  CAS  Google Scholar 

  120. Chikanza IC, Roux-Lombard P, Dayer J-M, et al. Dysregulated interleukin-1 receptor antagonist protein production in rheumatoid arthritis: pathogenetic implications. Arthritis Rheum 1995; 38: 642–8

    PubMed  CAS  Google Scholar 

  121. Chikanza IC, Sakkas L. Advances in the therapy of rheumatoid arthritis with biological agents. Emerging Drugs 2000; 5: 367–84

    CAS  Google Scholar 

  122. Grom AA, Murray KJ, Luyrink L, et al. Patterns of expression of tumor necrosis factor a, tumor necrosis factor b, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy. Arthritis Rheum 1996; 39: 1703–10

    PubMed  CAS  Google Scholar 

  123. Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human TNF: a predictive genetic model of arthritis. EMBO J 1991; 10: 4025–31

    PubMed  CAS  Google Scholar 

  124. Elliot MJ, Maini RN, Feldman M, et al. Treatment of rheumatoid arthritis with chimaeric mAb to TNF. Arthritis Rheum 1993; 36: 1681–90

    Google Scholar 

  125. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double blind comparison of chimaeric monoclonal antibody to tumour necrosis factor alpha (cA2) vs placebo in rheumatoid arthritis. Lancet 1994; 344: 1105–10

    PubMed  CAS  Google Scholar 

  126. Pearce GJ, Chikanza IC. Targeting tumour necrosis factor in the treatment of rheumatoid arthritis. BioDrugs 2001; 13: 139–49

    Google Scholar 

  127. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141–7

    PubMed  CAS  Google Scholar 

  128. Moreland LW, Baumgartner SW, Schiff MH, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999; 130: 478–86

    PubMed  CAS  Google Scholar 

  129. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253–9

    PubMed  CAS  Google Scholar 

  130. Finck B, Martin R, Fleischmann R, et al. A phase III trial of etanercept vs methotrexate in early rheumatoid arthritis (Enbrel ERA trial). Arthritis Rheum 1999; 42 Suppl.: S117

    Google Scholar 

  131. Lovell D, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile RA. N Engl J Med 2000; 342: 763–9

    PubMed  CAS  Google Scholar 

  132. Maini RM, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552–63

    PubMed  CAS  Google Scholar 

  133. Elliott MJ, Woo P, Charles P, et al. Suppression of fever and the acute phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumor necrosis factor-alpha (cA2). Br J Rheumatol 1997; 36: 389–93

    Google Scholar 

  134. Schattenkirchner M, Krüger K, Sander O, et al. Efficacy and tolerability of weekly subcutaneous injections of the fully human anti-TNF-antibody D2E7 in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 1998; 41: S57

    Google Scholar 

  135. Van De Putte LBA, Van Riel PLCM, Den Breeder A, et al. A single dose placebo controlled phase I study of the fully human anti-TNF-antibody D2E7 in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 1998; 41: S57

    Google Scholar 

  136. Van De Putte LBA, Rau R, Breedveld FC, et al. Efficacy of the fully human anti-TNF antibody D2E7 ion rheumatoid arthritis [abstract]. Arthritis Rheum 1999; 42: S400

    Google Scholar 

  137. Rau R, Herborn G, Sander O, et al. Long-term treatment with the fully human anti-TNF antibody D2E7 slows radiographic disease progression in rheumatoid arthritis [abstract]. Arthritis Rheum 1999; 42: S400

    Google Scholar 

  138. Fischer E, van Zee KJ, Morand MA, et al. IL-1Ra accumulates in experimental inflammation and human disease. Blood 1992; 79: 2192–200

    Google Scholar 

  139. Lebsack ME, Paul CC, Martindale JJ, et al. A dose and regimen ranging study of IL-1 receptor antagonist in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 1993; 36: S39

    Google Scholar 

  140. Campion GV, Lebsack ME, Lookabaugh J, et al. Dose range and dose frequency study of recombinant human IL-1Ra in patients with RA. The IL-1Ra Study Group. Arthritis Rheum 1996; 39: 1092–101

    PubMed  CAS  Google Scholar 

  141. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41: 2196–204

    PubMed  CAS  Google Scholar 

  142. Jiang Y, Genant HK, Watt I, et al. A multi-centre double blind, dose ranging randomised placebo controlled study of recombinant human IL-1Ra in patients with RA. Arthritis Rheum 2000; 43: 1001–9

    PubMed  CAS  Google Scholar 

  143. Cohen S, Hurd E, Cush JJ, et al. Treatment of IL-1Ra in combination with methotrexate in RA patients. Arthritis Rheum 1999; 42 Suppl.: S273

    Google Scholar 

  144. Wendling D, Radacot E, Wijdenes J. Treatment of severe RA by anti-IL-6 mAb. J Rheumatol 1993; 20: 259–62

    PubMed  CAS  Google Scholar 

  145. Isomaki P, Luukkanes R, Saario R, et al. IL-10 functions as an anti-inflammatory cytokine in rheumatoid arthritis. Arthritis Rheum 1996; 39: 386–95

    PubMed  CAS  Google Scholar 

  146. Kuhlmann F, Rohlig C, Lukoschek M, et al. Effects of IL-10 on synovial fluid mononuclear cells of patients with rheumatic diseases. Arthritis Rheum 1994; 37 Suppl.: S309

    Google Scholar 

  147. Maini RN, Paulus H, Breedveld FC, et al. rHuIL-10 in subjects with rheumatoid arthritis: a phase I and cytokine response study. Arthritis Rheum 1997; 40 Suppl.: S224

    Google Scholar 

  148. Van Den Bosch F, Russell A, Chir B, et al. rHuIL-4 in subjects with rheumatoid arthritis: a phase I dose escalating safety study. Arthritis Rheum 1998; 41 Suppl.: S56

    Google Scholar 

  149. Group GLS. Double blind controlled phase III multicenter clinical trial with interferon gamma in rheumatoid arthritis. Rheumatol Int 1992; 12: 175–85

    Google Scholar 

  150. Lemmel EM, Brackertz D, Franke M, et al. Results of a multicenter placebo-controlled double-blind randomized phase III clinical study of treatment of rheumatoid arthritis with recombinant interferon-gamma. Rheumatol Int 1998; 8: 87–93

    Google Scholar 

  151. Pernice W, Schuchmann L, Dippell J, et al. Therapy for systemic juvenile rheumatoid arthritis treated for one year with interferon-gamma. Z Rheumatol 1990; 49: 1–7

    Google Scholar 

  152. Coto C, Varela G, Hernandez V, et al. Use of recombinant interferon gamma in pediatric patients with advance juvenile chronic arthritis. Biotherapy 1998; 11: 15–20

    PubMed  CAS  Google Scholar 

  153. Gould D, Chikanza IC, Chernajovsky Y. Gene therapy targets for RA. Emerg Ther Targets 2000; 4: 481–95

    CAS  Google Scholar 

Download references

Acknowledgements

Dr Chikanza would like to thank the Arthritis Research Campaign (ARC) of the United Kingdom for their financial support.

Author information

Authors and Affiliations

  1. Bone and Joint Research Unit, St. Bartholomew’s and Royal London School of Medicine and Dentistry, Charterhouse Square, London, EC1M 6BQ, UK

    Ian C. Chikanza

  2. Department of Paediatrics, Royal London Hospital, London, UK

    Ian C. Chikanza

Authors
  1. Ian C. Chikanza
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ian C. Chikanza.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chikanza, I.C. Juvenile Rheumatoid Arthritis. Pediatr-Drugs 4, 335–348 (2002). https://doi.org/10.2165/00128072-200204050-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128072-200204050-00006

Keywords

Search

Navigation